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ABSTRACT
Objective To study the expression of interleukin (IL)-33
and to evaluate its relationship with macrophage
polarisation in artery biopsy specimens from patients with
giant cell arteritis (GCA).
Methods IL-33, ST2, p-STAT-6 and perivascular IL-1
receptor-associated kinase 1 (p-IRAK1) tissue distribution
was evaluated by immunohistochemistry. Inducible nitric
oxide synthase and CD163 were also used by
immunohistochemistry to evaluate the M1 and M2
polarisation, respectively. Quantitative gene expression
analysis of IL-33, T-helper (Th)2-related transcription
factor STAT6, Th2 cytokines (IL-4, IL-5, IL-25) and
interferon (IFN)-γ was performed in artery biopsy samples
obtained from 20 patients with GCA and 15 controls. Five
additional patients who had received prednisone when
the temporal artery biopsy was performed were also
enrolled.
Results IFN-γ and IL-33 were signiﬁcantly
overexpressed in the inﬂamed arteries of GCA patients.
IL-33 overexpression was not accompanied by a
concomitant increase of Th2 cytokines. Neovessels
scattered through the inﬂammatory inﬁltrates were the
main sites of IL-33 expression. The expression of IL-33
receptor ST2 and of p-IRAK1 was also increased in GCA
patients. Arteries from glucocorticoid-treated patients had
a lower expression of IL-33. IL-33 was accompanied by
the expression of p-STAT6 and a clear M2 macrophages
polarisation.
Conclusions A role for IL-33 in the inﬂammation of
GCA patients is supported by these ﬁndings.
INTRODUCTION
Giant-cell arteritis (GCA) is an inﬂammatory
disease of blood vessels most commonly involving
large and medium arteries of the head.1 The patho-
genesis of the disease is still unknown. Indeed,
several studies have demonstrated that both the
innate and adaptive immune system contribute to
GCA pathogenesis.2 3 T lymphocytes and macro-
phages in particular seem to be the main actors of
inﬂammation in GCA patients.4 5
The entry of inﬂammatory cells in artery
inﬂamed walls is mainly due to their interaction
with speciﬁc adhesion molecules expressed on the
inﬂamed endothelium. In GCA inﬂammation-
induced angiogenesis occurs. Neovessels and
advential vasa vasorum are the main sites where
adhesion molecules for leucocytes are expressed
and, therefore, the main sites through which
circulating leucocytes are recruited into the vascu-
lar bed.4
Interleukin (IL)-33, a member of the IL-1 cyto-
kine family,6 is a recently described novel activator
of endothelial cells, which promotes adhesion
molecules and proinﬂammatory cytokine expres-
sion in the endothelium and angiogenesis and vas-
cular permeability in vitro and in vivo.7–9
IL-33 may act both as a traditional cytokine
through activation of the IL-1 receptor-related
protein ST2 and as an intracellular nuclear factor
by translocating to the nucleus, where it binds to
the chromatin and modulates gene expression.10–12
IL-33 has also potent immune-modulating proper-
ties that are mediated by the downstream induc-
tion of cytokines and chemokines. Unlike the
other IL-1 family members, IL-33 primarily
induces T-helper (Th)2 immune responses and the
polarisation of macrophages through the alterna-
tive pathway of activation (the so-called M2
macrophages).13
In GCA all injury mechanisms have been related
to effector macrophages. Different pathways of
macrophage activation have been described in
humans with classically activated M1 macro-
phages, mainly inducing tissue inﬂammation and
M2 macrophages involved in tissue repair and
remodelling.14–16 Consistently with Th1 immune
response M1 macrophages seem to be mainly
involved in the pathogenesis of GCA4 5 even if the
exact contribution of M2 macrophages has not yet
been investigated.
The role of IL-33 in human inﬂammatory dis-
eases, such as rheumatoid arthritis and psoriasis,
has been demonstrated, identifying IL-33 as a
potential therapeutic target in chronic inﬂamma-
tion.7 17–21 Whether this cytokine could be impli-
cated in the immune response characteristic of
GCA is still unknown.
In the present study we investigated the expres-
sion of IL-33 and its relationship with the macro-
phage polarisation in the inﬂamed arteries of GCA
patients.
METHODS
Patients
Twenty consecutive patients (15 women, ﬁve men)
diagnosed as having GCA were studied. Fifteen
patients had evidence of classic transmural inﬂam-
mation while ﬁve displayed a small-vessel vascu-
litis (SVV) surrounding an uninﬂamed temporal
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artery. These ﬁve patients satisﬁed the American College of
Rheumatology 1990 criteria for the classiﬁcation of GCA.22
Furthermore, none of these ﬁve patients had clinical manifesta-
tions suggesting a systemic vasculitis other than GCA when
temporal artery biopsy was performed or during the follow-up
period (median 34.5 months).
Their median age was 75 years (range 60–85 years). The
erythrocyte sedimentation rate was 74 mm/h (range 68–120).
Headache and artery tenderness and/or decreased or absent
temporal artery pulsation were present in 16 out of 20 patients.
At the time of diagnosis no patients were receiving steroids and
ﬁve patients had vision loss. Polymyalgia rheumatica was asso-
ciated in ﬁve patients.
To assess the effect of glucocorticoids on IL-33 expression we
also consecutively selected temporal artery samples from ﬁve
additional patients with biopsy-conﬁrmed GCA who had
received prednisone (1 mg/kg per day) for an average of 21 days
(range 8–33) when the temporal artery biopsy was excised.
To evaluate the baseline inﬂammatory response at the time
of diagnosis four parameters (score ranges from 0 to 4) were
used: fever, weight loss, erythrocyte sedimentation rate of
85 mm/h or greater and haemoglobin less than 11.0 mg/dl.
Fifteen histologically normal temporal artery samples from
15 consecutive patients, matched for sex and age (12 women,
three men; median 75.8 years, range 66–85 years) with sus-
pected GCAwho had negative biopsy results served as controls.
However, to be sure the patients were really negative controls
we excluded biopsy-negative patients satisfying American
College of Rheumatology 1990 GCA classiﬁcation criteria22 and
patients treated with corticosteroids. Furthermore, the control
patients had a long follow-up period (median 44 months) and
they never developed clinical manifestations related to GCA or
other vasculitis. From 11 patients with biopsy-conﬁrmed GCA
and ﬁve controls, total RNA was extracted from frozen frag-
ments of the temporal artery biopsies excised before starting
treatment.
The study was approved by the ethics committee of local
institutions. Patients’ signed informed consent for the collec-
tion and storage of biological material was also obtained.
Histological assessment
Biopsy specimens were evaluated by two experienced patholo-
gists (AR and AC) and classiﬁed into three main categories: (1)
classic GCA if histological examination of temporal artery biop-
sies showed transmural inﬁltration predominantly of lympho-
mononuclear cells in the temporal artery wall, with or without
giant cells; (2) SVV surrounding an uninﬂamed temporal artery
if histological examination of temporal artery biopsies showed
aggregates of inﬂammatory mononuclear cells arranged around
capillaries essentially located in the connective tissue around
the adventitia and absence of inﬂammation in temporal
artery;23 (3) biopsy specimens without evidence of inﬂamma-
tion in temporal artery and in the surrounding connective
tissue. Numbers of neovessels distributed within the wall of
inﬂamed arteries were counted and expressed as the median of
the number of microvessels in three random high-power micro-
scopic ﬁelds (400× magniﬁcation).
Immunohistochemical analysis of GCA biopsy samples
Tissue samples were immediately ﬁxed with 4% formaldehyde
and embedded in parafﬁn. Immunohistochemistry for IL-33
and ST2 was performed on 5-μm-thick parafﬁn-embedded sec-
tions from arteries and from tonsils (used as positive controls)
as previously described.3 The primary antibodies mouse
monoclonal anti-human IL-33 (1 : 200 dilution; Novus
Biological, Littleton, Colorado, USA), rabbit polyclonal anti-
human ST2 (dilution 1 : 100; Novus Biological), rabbit anti-
human p-STAT6 (p Tyr 641) (dilution 1 : 100; Novus
Biological), rabbit anti-human perivascular IL-1 receptor-
associated kinase 1 (p-IRAK1) (clone H-273) (dilution 1 : 25;
Santa Cruz Biotechnology, Mill Valley, California, USA), mouse
anti-human CD68 (macrophages) (clone PG-M1) (dilution 1 :
200; Dako A/S, Cambridge, UK) and mouse anti-human-
CD163 (clone 10D6) (dilution 1 : 100; Novocastra, Newcastle,
UK) were added and incubated for 1 h at room temperature.
Isotype-matched irrelevant antibodies were used as a negative
control (mouse IgG1 monoclonal antibody (ab27479) and
rabbit IgG polyclonal antibody (ab27472), AbCam, Cambridge,
UK). Following three washes with Tris-buffered saline, slides
were incubated for 30 min with peroxidase-conjugated Dako
EnVision polymer. After three further washings, peroxidase
activity was visualised using diaminobenzidine chromogen
(Dako), and slides were lightly counterstained with haematoxy-
lin before dehydration and mounting in DePex (VWR
International, Oslo, Norway). The number of IL-33 and
CD-163-expressing cells was determined by counting IL-33
immunoreactive cells on photomicrographs obtained from three
random high-power microscopic ﬁelds (400× magniﬁcation)
under a Leica DM2000 optical microscope, using a Leica
DFC320 digital camera (Leica, Rijswijk, The Netherlands).
RNA extraction from temporal artery biopsies and quantitative
TaqMan reverse transcriptase PCR for IFN-γ, IL-4, IL-5, IL-25,
IL-33 and STAT6
Temporal artery biopsies were stored soon after removal in
RNAlater solution (Applied Biosystems, Foster City, California,
USA). Each sample was lysed in a tissue homogeniser and RNA
was extracted using the commercially available illustra
RNAspin Mini Isolation Kit (GE Healthcare, Little Chalfont,
Bucks, UK), according to the manufacturer ’s instructions. Total
RNAwas reverse-transcribed to complementary DNA using the
high capacity cDNA reverse transcription kit (Applied
Biosystems). Samples were stored at −20°C until use. For quan-
titative TaqMan real-time PCR, master mix and Taqman gene
expression assays for GAPDH control and for interferon (IFN)-γ
(Hs00989291_m1), IL4 (Hs00166237_m1), IL-5 (Hs00602482_
m1), IL-25 (Hs03044841_m1), IL33 (Hs01125942_m1) and
STAT6 (Hs00598625_m1) were obtained from Applied
Biosystems. Samples were run in triplicate using the step-one
real-time PCR system (Applied Biosystems). Relative changes in
gene expression between control and arteritis samples were
determined using the ΔΔCt method. Levels of the target tran-
script were normalised to a GAPDH endogenous control, con-
stantly expressed in both groups (ΔCt). For ΔΔCt values,
additional subtractions were performed between arteritis and
control ΔCt values. Final values were expressed as fold of
induction.
Statistical analysis
Statistical analysis of quantitative variables was performed
using the Mann–Whitney rank-sum test. Correlation analyses
were performed by using the Pearson product moment correl-
ation. p Values less than 0.05 were considered signiﬁcant.
RESULTS
Clinical and histological features
Fifteen of 20 patients with untreated GCA had evidence of
classic transmural inﬂammation while ﬁve displayed SVV
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surrounding a non-inﬂamed temporal arteritis or an isolated
vasa vasorum vasculitis. All patients treated with steroids dis-
played transmural inﬂammation. Of the 15 patients with trans-
mural inﬂammation one or fewer inﬂammatory parameters
were observed in two patients and two or more inﬂammatory
parameters were observed in 13. Two out of the ﬁve patients
with SVV had one or fewer inﬂammatory parameters and the
remaining displayed two or more inﬂammatory parameters.
IL-33 and ST-2 expression in the inﬂamed arteries of GCA
patients
We evaluated the expression of IL-33 and its receptor ST2 at
the protein level and its distribution within the tissue.
Intense IL-33 staining was observed only in inﬂamed arteries
(ﬁgure 1A–F). In particular, patients with SVV displayed IL-33
expression among inﬂammatory mononuclear cells arranged
around capillaries located in the connective tissue around the
adventitia (ﬁgure 1B). In classic transmural inﬂammation IL-33
immunoreactivity was observed in the context of granulomas
and some scattered cells of the inﬂammatory inﬁltrates (ﬁgure
1C–E). IL-33 expression was also observed in microvessels dis-
tributed within the vessel wall of inﬂamed arteries that we
considered as neovessels resulting from inﬂammation-
dependent angiogenesis (ﬁgure 1F). A weak expression of IL-33
was also observed among vascular smooth muscle cells in both
subgroups of patients (ﬁgure 1B–C).
As IL-33 induces endothelial activation and angiogenesis
through ST2/TRAF6-mediated endothelial nitric oxide produc-
tion,13 we also evaluated the tissue expression and distribution
of ST2 in the arterial wall of patients and controls. As shown
in ﬁgure 2, ST2 expression was observed only in the inﬂamed
arteries (ﬁgure 2A–B). In particular, the endothelial cells of
newly formed vessels (ﬁgure 2C), some scattered cells of the
inﬂammatory inﬁltrates (ﬁgure 2D) and granulomas (ﬁgure 2E)
were the main cells positive for ST2 in patients displaying
transmural inﬂammation. Of importance is the observation
that the same vessels that overexpress IL-33 are intensely posi-
tive for ST-2 (ﬁgures 1F and 2C). Immunoreactivity for ST2
was not clearly observed in temporal arteries with SVV (data
not shown). As the signal of IL-33/ST2 is mediated through
the IL-1 signalling pathway,24 we also studied the expression of
IRAK1 to demonstrate the functional relevance of IL-33. As
shown in ﬁgure 3, p-IRAK1 was overexpressed in the inﬂamed
artery wall of patients with transmural inﬂammation.
IL-33 mRNA is overexpressed in the inﬂamed arteries of GCA
patients
We also investigated whether arterial inﬂammation in GCA
patients was characterised by upregulation of IL-33 and Th2
cytokines such as IL-4, IL-5, IL-25 and the Th2-related nuclear
transcription factor STAT6. As shown in ﬁgure 4A a marked
and signiﬁcant increase in arterial expression of IL-33 tran-
scripts was observed in GCA patients with both transmural
inﬂammation and SVV compared with control artery biopsy
specimens (p<0.001 and p<0.05, respectively). IL-33 expression
in GCA patients with transmural inﬂammation was correlated
with the number of inﬂammatory parameters, as described in
the Methods section (r2= 0.5663, p=0.0012) (ﬁgure 4B) and
with the numbers of neovessels (r2= 0.49, p=0.0035) (ﬁgure 4C).
Of relevance, the expression of Th2-related cytokines IL-4, IL-5,
IL-25 was absent in the inﬂamed arteries of GCA patients (data
not shown), suggesting a role for IL-33 outside the context of a
Th2 response. Interestingly, STAT6 was signiﬁcantly increased
only in the inﬂamed arteries of patients with transmural
inﬂammation compared to controls (p<0.001) (ﬁgure 4D). A
trend towards an increase in STAT6 expression was also
observed in patients with SVV, although statistical signiﬁcance
was not achieved, probably due to the low number of patients
enrolled. The function of STAT molecules is reﬂected by their
phosphorylation status, thus we investigated phospho-STAT-6
Figure 1 Interleukin (IL)-33 expression in temporal arteries of patients with giant cell arteritis (GCA). Representative photomicrographs showing
5-μm-thick parafﬁn-embedded sections of artery biopsy specimens obtained from controls (A) and patients with GCA (B–F), stained for IL-33. IL-33
expression was observed in inﬂamed arteries displaying small vessel vasculitis (SVV) (B) and transmural inﬂammation (C). In SVV IL-33 expression
was observed among inﬁltrating mononuclear cells (arrows) and smooth vascular muscle cells (B). In arteries displaying transmural inﬂammation
IL-33 expression was observed among inﬁltrating inﬂammatory mononuclear cells (D) and giant cells scattered through the inﬂamed wall of inﬂamed
arteries (E). Microvessels distributed through the inﬂammatory inﬁltrates also showed intense IL-33 positivity (arrows) (F). (A, original magniﬁcation
×100; B–C, original magniﬁcation ×250; D–F, original magniﬁcation ×400).
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protein expression. Increased expression of p-STAT6 was con-
ﬁrmed in the inﬂamed arteries of GCA patients with trans-
mural inﬂammation by immunohistochemical analysis (ﬁgure
4E–F).
Macrophages in the arteries of GCA patients
As IL-33 has been reported to act on naive macrophages indu-
cing a M1 phenotype but also enhancing the differentiation of
alternatively activated macrophages (M2), we evaluated the M1
and M2 macrophages in the inﬂamed arteries of GCA patients.
Inducible nitric oxide synthase and CD163 were used to charac-
terise M1 and M2-polarised macrophages, respectively.
In our study a signiﬁcantly increased expression of IFN-γ
(ﬁvefold increase, p<0.001, data not shown) and a concomitant
expansion of M1 macrophages (ﬁgure 5) was evident in both
the arteries with transmural inﬂammation (ﬁgure 5C) and SVV
(ﬁgure 5E), suggesting the occurrence in inﬂamed arteries of a
Th1-mediated macrophage activation.
Interestingly, M2 macrophages were also signiﬁcantly
expanded in the inﬂamed arteries of GCA patients (ﬁgure 5D–F)
and their presence was signiﬁcantly correlated with the levels of
IL-33 messenger RNA (r2= 0.6652 , p=0.002) (data not shown).
As other Th2 cytokines were virtually absent, we argue that
IL-33 could be responsible for the M2 polarisation observed in
GCA patients.
Glucocorticoid therapy modulates IL-33 expression
To analyse the effect of glucocorticoid therapy on IL-33 expres-
sion we cross-sectionally compared the mRNA levels and
protein expression in arteries from active versus glucocorticoid-
treated GCA patients. As shown in ﬁgure 6A, in glucocorticoid-
treated arteries the expression of IL-33 mRNA was similar to
control arteries. Accordingly, the expression of IL-33 at protein
level and the numbers of IL-33+ cells were reduced in
glucocorticoid-treated arteries when compared to untreated
samples (ﬁgure 6B–C).
DISCUSSION
GCA is a vasculitis of large and medium size vessels whose
pathogenesis is actually unknown. A key role in the pathogen-
esis seems to be played by endothelial cells, which are essential
in the induction and perpetuation of the inﬂammatory
process.1 5 In GCA, the endothelial cells primarily involved
appear to be those of the adventitial vasa vasorum, particularly
in early inﬁltration of the artery wall25 and of the newly
formed vessels. It is, in fact, at this level that overexpression of
adhesion molecules and pro-inﬂammatory cytokines occurs.3 26
In GCA inﬂammation and angiogenesis seems to be closely
associated.26 27 Interplay between inﬂammation and
Figure 2 ST2 expression in temporal arteries of patients with giant cell arteritis (GCA). Representative photomicrographs showing 5-μm-thick
parafﬁn-embedded sections of artery biopsy specimens obtained from controls (A) and patients with GCA (B–E), stained for ST2. Abundant ST2
expression was observed in microvessels distributed through the inﬂammatory inﬁltrates (B–C). ST2 expression was also observed in inﬁltrating
inﬂammatory mononuclear cells (D) and some giant cells scattered through the inﬂamed wall of inﬂamed arteries (E). (A–B, original magniﬁcation
×100; C–E, original magniﬁcation ×250).
Figure 3 Perivascular IL-1 receptor-associated kinase 1 (p-IRAK1)
expression in temporal arteries of patients with giant cell arteritis
(GCA). Representative photomicrographs showing 5-μm-thick
parafﬁn-embedded sections of artery biopsy specimens obtained from
controls (A) and patients with GCA (B), stained for p-IRAK1. Abundant
p-IRAK1 expression was prevalently observed in mononuclear cells
scattered through the wall of inﬂamed GCA arteries (A–B, original
magniﬁcation ×250).
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angiogenesis is largely mediated by cytokines, chemokines and
growth factors, and some of these molecules, including IL-6
and vascular endothelial growth factor, have been demonstrated
to be increased in GCA.28
In the present study we demonstrated an intense expression
of IFN-γ, IL-33, ST2 and STAT6 in the inﬂamed arteries of
GCA patients. The increased expression of IL-33 and its recep-
tor ST2 was mainly observed in endothelial cells of newly
formed vessels. Interestingly, IL-33 expression was correlated
with the numbers of inﬂammatory parameters suggesting a
participation of IL-33 as a pro-inﬂammatory cytokine. Both M1
and M2 macrophages were also signiﬁcantly increased in the
inﬂamed arteries.
IL-33 is a member of the IL-1 cytokine family.6 IL-33 is con-
stitutively expressed by endothelial and epithelial cells and is
released by these cells following necrotic cell death; for this
reason this cytokine has been referred to as an alarmin.8 10 11
In GCA arteries, IL-33 expression was also observed in vascular
smooth muscle cells of the inﬂamed arteries with adventitial
inﬂammation. It has been shown that vascular smooth muscle
cells are exposed to oxidative damage29 30 and IL-33 expression
by vascular smooth muscle cells could suggest an ‘alarmin’
function.
IL-33 is a nuclear protein that is also released into the extra-
cellular space, thus acting as a dual-function molecule.6
Extracellular IL-33 binds to the cell-surface receptor ST2,
leading to the activation of intracellular signalling pathways
similar to those used by IL-1. ST2 is expressed mainly in mast
cells, macrophages and Th2 cells.13 31 ST2 has also been
demonstrated to be highly expressed in freshly isolated human
umbilical vein endothelial cells, and upregulated by the
pro-inﬂammatory cytokines TNFα, IL-1α and IL-1.7 IL-33 has
been demonstrated to promote angiogenesis and vascular
leakage.12 Our demonstration of IL-33 and ST2 intense endo-
thelial positivity together with the positive correlation
observed between IL-33 and the numbers of neovessels suggests
a role of IL-33 in the pathogenesis of angiogenesis-dependent
inﬂammation in GCA. Upon stimulation of ST2/IL-1R, IRAK1,
one of the two putative serine-threonine kinases, undergoes
phosphorylation following activation.32 The increased expres-
sion of p-IRAK1 observed in the inﬂamed arteries could
support the functional relevance of IL-33 and ST2 expression.
In this regard the observation of a signiﬁcant reduction of IL-33
in glucocorticoid-treated patients appears to be of interest and
suggests that the efﬁcacy of glucocorticoids on the manifesta-
tions of GCA and tissue composition of the inﬂammatory inﬁl-
trates could be at least partly related to the suppression of the
IL-33 axis.
Through ST2 interactions IL-33 induces helper T cells, mast
cells, eosinophils and basophils to produce type 2 cytokines. In
our study, however, IL-33 overexpression was not accompanied
by an increased expression of Th2-related cytokines such as
IL-4, IL-5, IL-25. The number of samples tested was, however,
too small really to conﬁrm this observation.
The Th2-related transcription factor STAT6 was also signiﬁ-
cantly upregulated at both mRNA and protein levels in the
transmural inﬂamed arteries. Beyond the role of STAT6 in indu-
cing Th2 polarisation, STAT6 has been shown also to be
Figure 4 Interleukin (IL)-33 and STAT6 gene expression in temporal arteries from patients and controls (HC). Relative mRNA quantiﬁcation of IL-33
(A) and STAT6 (D) was assessed by quantitative reverse transcriptase PCR in arterial biopsy specimens from patients with transmural (GCA) and
perivascular inﬂammation (p-GCA) and controls. A, D, data are shown as mean (SD). *p<0.001; **p<0.05. IL-33 mRNA expression was correlated
with the numbers of inﬂammatory parameters (B) and neovessels (C). E–F, Representative photomicrographs showing 5-μm-thick parafﬁn-embedded
sections of artery biopsies obtained from controls (E) and patients with GCA (F), stained for p-STAT-6 (E–F, original magniﬁcation ×250).
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involved in the signalling of IL-27, a Th1 cytokine that we
have recently demonstrated to be increased in inﬂamed arteries3
suggesting a potential role for STAT6 independent of the Th2
response in GCA.
IL-33 is a crucial ampliﬁer of mucosal and systemic innate
immune responses potentiating lipopolysaccharide-mediated
cytokine production by macrophages.33 In this regard we inves-
tigated macrophage polarisation in GCA. Macrophages are rou-
tinely categorised into two main phenotypic subtypes based on
gene expression induced in response to cytokine and pathogen-
derived stimulation,16 the classically activated macrophages
(M1 macrophages) and the alternatively activated macrophages
(M2 macrophages). Human macrophages express ST2 and
respond to the presence of IL-33 in a different manner depend-
ing on the activation status of these cells.16 When added to M1
or M2 polarising or polarised conditions, IL-33 promoted the
expression of M2 chemokine markers.13 In our study both M1
and M2-polarised macrophages were signiﬁcantly increased. M1
macrophage polarisation was accompanied by a signiﬁcantly
increased expression of IFN-γ. The increased number of M2
macrophages was correlated with the levels of IL-33, suggesting
that M2 polarisation may be attributable to a direct effect of
IL-33 on naive macrophages.
In conclusion, this is the ﬁrst study demonstrating that the
expression of IL-33 and its receptor ST2 is increased in the
inﬂamed arteries of untreated GCA patients and is suppressed
in glucocorticoid-treated patients. IL-33 in the inﬂamed arteries
could act earlier in artery inﬂammation promoting angiogen-
esis, vascular leakage and tissue inﬁltration by inﬂammatory
cells. IL-33 may also modulate the innate immune responses
through the regulation of macrophage effector functions.
Finally, the increased M2 response we observed in this study
may suggest that this speciﬁc macrophage activation status
may play a role in the pathogenesis of GCA.
Figure 6 Interleukin (IL)-33 expression in temporal arteries from glucocorticoid-treated patients. (A) Relative mRNA quantiﬁcation of IL-33 assessed
by quantitative reverse transcriptase PCR (data are shown as mean (SD); *p<0.001; **p<0.05). (B) Representative photomicrograph showing
5 μm-thick parafﬁn-embedded sections of artery biopsy specimens obtained from glucocorticoid-treated patient stained for IL-33. (C) Quantiﬁcation of
IL-33+ cells in artery samples from steroids untreated and treated patients and controls (HC). Data are shown as mean (SD). *p<0.0001; **p<0.05.
Figure 5 M1 and M2 macrophages in the temporal arteries of patients with giant cell arteritis (GCA). Representative photomicrographs showing
5-μm-thick parafﬁn-embedded sections of artery biopsy specimens obtained from controls (A–B) and patients with GCA displaying transmural
inﬂammation and small vessel vasculitis (SVV) (C–F), stained for inducible nitric oxide synthase (iNOS) (a marker of M1 polarisation) and CD163 (a
marker of M2 polarisation). A–B, control arteries stained for iNOS (A) and CD163 (B). iNOS+ (C) and CD163+ (D) macrophages were abundantly
expressed in the wall of inﬂamed arteries with transmural inﬂammation. iNOS+ (E) and CD163 (F) macrophages in the wall of inﬂamed arteries with
SVV. (A–F, original magniﬁcation ×100).
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Correction
Ciccia F, Alessandro R, Rizzo A, et al. IL-33 is overexpressed in the inﬂamed arteries of patients
with giant cell arteritis. Ann Rheum Dis 2013;72:258–64. Images in ﬁgures 1F and 2C of this
paper were identical. The correct ﬁgure 1 is given below.
Ann Rheum Dis 2015;74:920. doi:10.1136/annrheumdis-2012-201309corr1
Figure 1 Interleukin (IL)-33 expression in temporal arteries of patients with giant cell arteritis (GCA).
Representative photomicrographs showing 5-μm-thick parafﬁn-embedded sections of artery biopsy specimens
obtained from controls (A) and patients with GCA (B–F), stained for IL-33. IL-33 expression was observed in
inﬂamed arteries displaying small vessel vasculitis (SVV) (B) and transmural inﬂammation (C). In SVV IL-33
expression was observed among inﬁltrating mononuclear cells (arrows) and smooth vascular muscle cells (B).
In arteries displaying transmural inﬂammation IL-33 expression was observed among inﬁltrating inﬂammatory
mononuclear cells (D) and giant cells scattered through the inﬂamed wall of inﬂamed arteries (E). Microvessels
distributed through the inﬂammatory inﬁltrates also showed intense IL-33 positivity (arrows) (F). (A, original
magniﬁcation ×100; B–C, original magniﬁcation ×250; D–F, original magniﬁcation ×400).
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